Diazoxide
As of the edition of 20 October 2026, Diazoxide is a small molecule: marketed, first approved in 1978 (CH); acts on KCNJ11 and KCNJ8; no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2008
- Kind
- Small molecule
- Brand name
- Proglycem
- First approved
- 1 December 1978 (CH)
- Approvals on record
- 11 in 5 regions
- Holder of the most recent approval
- Neurocrine; 3 holders in all
- Registered trials
- 27, 8 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Inherited and neonatal; Heart and blood vessels; Immune system; Nervous system
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Neurocrine holds a later exclusivity on its own new formulation or combination product, ending 2032; it does not protect the original drug.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 2 | 1 | 0 |
| Phase 1 | 8 | 4 | 1 | 3 |
| Phase 2 | 11 | 5 | 1 | 3 |
| Phase 3 | 2 | 1 | 0 | 0 |
| Phase 4 | 3 | 1 | 0 | 2 |
| All trials | 27 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Applicant | 1978 to now |
| Neurocrine | Later holder and Lead sponsor of trials | 2008 to now |
| Teva | Acquired holder | 2013 to now |